Could a diabetes drug shrink dangerous belly fat in HIV patients?
NCT ID NCT04019197
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether semaglutide, a drug used for diabetes, can reduce harmful belly fat and improve heart health in people with HIV who have excess fat around the midsection (lipohypertrophy). About 108 participants will receive either semaglutide or a placebo for 32 weeks. The goal is to see if the drug can lower fat in the belly and around organs, and reduce inflammation and heart disease risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States